Drugs / MRT5410
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05624606 | Nov 2022 → Mar 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT5410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05624606 ↗ |
| Modality | Messenger RNA (mRNA) | “Quadrivalent Influenza mRNA Vaccine MRT5410” NCT05624606 ↗ |